Open AccessSarcopenia/Muscle Mass is not a Prognostic Factor for Short‐ and Long‐Term Outcome After Esophagectomy for Cancer
Author(s) -
Grotenhuis Brechtje A.,
Shapiro Joël,
Adrichem Stefan,
Vries Marianne,
Koek Marcel,
Wijnhoven Bas P. L.,
Lanschot J. Jan B.
Publication year - 2016
Publication title -
world journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.115
H-Index - 148
eISSN - 1432-2323
pISSN - 0364-2313
DOI - 10.1007/s00268-016-3603-1
Subject(s) - sarcopenia , medicine , esophagectomy , esophageal cancer , chemoradiotherapy , sarcopenic obesity , overweight , cancer , neoadjuvant therapy , surgery , oncology , breast cancer , body mass index
Background Recent studies have suggested that sarcopenia is a prognostic risk indicator of postoperative complications and predicts survival in cancer patients. The aim of this study is to investigate whether sarcopenia is associated with postoperative short‐term outcome (morbidity and mortality) and long‐term survival in patients undergoing esophagectomy for cancer after neoadjuvant chemoradiotherapy. Methods All patients who underwent neoadjuvant chemoradiotherapy followed by esophagectomy for cancer, and of whom an adequate CT scan was available, were included in the current study. The presence of sarcopenia was defined by CT imaging using cut‐off values of the total cross‐sectional muscle tissue measured transversely at the third lumbar level. Results A total number of 120 patients were eligible for analysis. Almost half of the patients ( N = 54, 45 %) were classified as having sarcopenia; 24 sarcopenic patients (44 %) had overweight and 5 sarcopenic patients (9 %) were obese. Overall morbidity and mortality rate did not differ significantly between sarcopenic and non‐sarcopenic patients, nor did long‐term overall or disease‐free survival. Also sarcopenic obesity was not associated with worse outcome. Conclusion The presence of sarcopenia was not associated with a negative short‐ and long‐term outcome in this selected group of esophageal cancer patients after neoadjuvant chemoradiotherapy followed by esophagectomy.